Search Medical Condition
Please enter condition
Please choose location from dropdown

Saint Priest En Jarez, France Clinical Trials

A listing of Saint Priest En Jarez, France clinical trials actively recruiting patients volunteers.

Found (346) clinical trials

Phase II Study of Regorafenib as Maintenance Therapy

Patients will be randomized 1:1 using a centralized randomization software, assuring concealment, with a minimization program controlling for the following factors: Histological subgroups: leiomyosarcoma versus synovial sarcoma versus other histological subtype Response to doxorubicin-based chemotherapy: partial response versus stable disease Centers The treatment will be administrated as long as it …

Phase

0.0 miles

Learn More »

A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France

Eligible patients will be identified and invited to enroll from approximately 100 dermatologists in France practicing in public hospitals (or private clinics) or private practice. Patients will be followed over 12 months after initiation of apremilast or until discontinuation of apremilast whatever the earlier. Given the observational nature of the …

Phase N/A

0.0 miles

Learn More »

Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Non Small Cell Lung Cancer (NSCLC) remains the leading cause of death by cancer in the world. Because of the increase in lung cancer incidence with age and the increase of life expectancy, about half of the patients are patients aged 70 or older. Several clinical trials have shown the …

Phase

0.0 miles

Learn More »

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

This is a randomized, multicenter, double-blind, parallel-group, active-control study. Approximately 280 patients aged 18 years will be enrolled in the study globally. The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor antagonist. The active control is irbesartan. The purpose of the study is to evaluate …

Phase

0.0 miles

Learn More »

Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)

Approximately 400 eligible subjects will be randomized to one of the following 2 treatment arms Investigational Arm: Sacituzumab Govitecan 10 mg/kg via IV injection administered on Day 1 and Day 8 (21-day cycle). Control Arm: Recommended doses and schedules as per NCCN guidelines (with dose modifications if too toxic). Eribulin; …

Phase

0.01 miles

Learn More »

Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

The combination of venetoclax (V) and ibrutinib (I) has recently emerged as a very effective therapy in both relapse and front-line settings. The preliminary results of the CLARITY (R/R CLL) and CAPTIVATE (untreated CLL) studies have demonstrated the promising potential of the I+VEN combination, which led to a very high …

Phase

0.01 miles

Learn More »

Nivolumab With Gemcitabine Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

International, multicentre, randomised, open-label, treatment optimisation study, preceded by safety run-in phases conducted for B-cell and T-cell lymphoma separately.

Phase

0.01 miles

Learn More »

NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.

The aim of NiQoLe is to evaluate tolerability of Niraparib and the management by the physicians of the side-effects in real life in France. The study will also generate data on longitudinal follow up of closed symptoms and side effects reported by the patients especially with the NCI PRO (Patient-Reported …

Phase

0.01 miles

Learn More »

A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer

Post-menopausal women with histologically or cytologically confirmed metastatic or loco-regionally recurrent ER-positive HER2-negative breast cancer before randomization and fulfilling all of the inclusion criteria and none of the exclusion criteria will be included. After the screening visit and confirmation of eligibility, patients will be randomly assigned in a 1:1:1:1 ratio …

Phase

0.01 miles

Learn More »

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in combination with other therapies will be monitored. For this study, …

Phase N/A

0.1 miles

Learn More »